Tohru Kitada is currently CEO of Otawa-Kagaku, Parkinson Clinic and Research. He graduated from Niigata University School of Medicine and obtained his M.D. in 1990. By 2003, he had completed his training in neurology at Juntendo Hospital and obtained board certification in neurology. During this time, he also studied molecular biology at Keio University from 1995 to 1999, where he collaborated with two others to discover the parkin gene and register it in GenBank in 1997, reported the structure and genetic variants of the parkin gene in Nature in 1998, and received his Ph.D. in 1999 for this work. He named this gene parkin. In 2003, he joined Professor Jie Shen’s lab at Harvard University, where he succeeded in creating and analyzing the first PINK1 gene-deficient mice in the world. These mice have since been used worldwide for research on Parkinson’s disease. In 2010, he moved to the University of Ottawa and returned to clinical practice. At the same time, he focused his research on the redox function of Parkin, discovering that Parkin directly reacts with and scavenges hydrogen peroxide, a mitochondrial reactive oxygen species. In 2018, he returned to Japan and established Otawa-Kagaku for clinical work and research on Parkinson’s disease, and he began collaborative research with Dr. Haque of UAE University. The goal of the current study is to investigate the function of Parkin as a redox molecule in mitochondria and Lewy bodies and its interrelationship with α-synuclein.